Drugging homologous recombination: back to the future
In this editorial, published recently in Future Medicinal Chemistry, authors Hannah Sanford-Crane, Tanja Pejovic and Xiangshu Xiao discuss the potential of homologous recombination inhibitors as novel anticancer therapies.
Please sign in or register for FREE
Sign in to RxNet
Register to RxNet
RxNet is a communal space where industry and academic professionals can come together to discuss the latest research and developments, share thoughts and opinions, and build valuable international relationships.